Menopause Practice Questions

Q: Hormone replacement therapy is not indicated for which of the following conditions?

Prevention of coronary artery disease. **Explanation:** The primary goal of Hormone Replacement Therapy (HRT) is the management of menopausal symptoms and the prevention of bone loss. **Why Option D is correct:** Historically, it was believed that HRT provided cardioprotection. However, large-scale clinical trials, specifically the **Women’s Health Initiative (WHI)**, demonstrated that HRT (especially combined estrogen-progestogen) does not prevent coronary artery disease (CAD). In fact, initiating HRT in older postmenopausal women may **increase** the risk of thromboembolic events and cardiovascular morbidity. Therefore, HRT is strictly **not indicated** for the primary or secondary prevention of CAD. **Analysis of Incorrect Options:** * **A. Urogenital atrophy:** Estrogen deficiency leads to vaginal dryness, dyspareunia, and urinary urgency. Low-dose topical or systemic HRT is the gold standard treatment for these symptoms. * **B. Vasomotor symptoms:** Hot flashes and night sweats are the most common indications for HRT. It remains the most effective treatment for moderate-to-severe vasomotor instability. * **C. Prevention of osteoporosis:** Estrogen inhibits osteoclast activity. HRT is FDA-approved for the prevention of postmenopausal osteoporosis, particularly in women at high risk of fractures who cannot tolerate other therapies. **High-Yield Clinical Pearls for NEET-PG:** * **Window of Opportunity Hypothesis:** HRT is safest and most effective when started within 10 years of menopause or before age 60. * **Contraindications:** Undiagnosed vaginal bleeding, active liver disease, history of VTE, and estrogen-dependent tumors (Breast/Endometrial CA). * **Addition of Progestogen:** In women with an intact uterus, progestogen must be added to estrogen to prevent **endometrial hyperplasia/carcinoma**. For women post-hysterectomy, Estrogen-only therapy (ERT) is used.

Q: Menopause is diagnosed by which of the following biochemical parameters?

FSH>40 IU/L. ### Explanation **Correct Answer: C. FSH > 40 IU/L** **Why it is correct:** Menopause is defined as the permanent cessation of menstruation due to the loss of ovarian follicular activity. As the ovarian reserve depletes, there is a significant drop in **Inhibin B** and **Estradiol**. The loss of negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis leads to a compensatory rise in Gonadotropins. **Follicle Stimulating Hormone (FSH)** is the most sensitive biochemical marker for menopause. A serum FSH level **>40 IU/L** (on two occasions, 1 month apart) is considered diagnostic, though levels >30 IU/L in the presence of amenorrhea are clinically highly suggestive. **Why the other options are incorrect:** * **A. Estradiol >20 pg/ml:** In menopause, estradiol levels typically **decrease** significantly, usually falling **below 20 pg/ml**. High levels would indicate active follicular development. * **B. Progesterone 20–30 IU/L) due to the lack of feedback inhibition, but FSH rises earlier and more significantly than LH, making FSH the preferred marker. **High-Yield Clinical Pearls for NEET-PG:** 1. **Earliest biochemical change** of perimenopause: Decrease in **Inhibin B**. 2. **Most sensitive marker** for ovarian reserve: **AMH (Anti-Müllerian Hormone)**; it decreases before FSH rises. 3. **FSH/LH Ratio:** In menopause, the ratio is **>1** (FSH rises more than LH). 4. **Clinical Diagnosis:** Menopause is primarily a retrospective clinical diagnosis (12 months of amenorrhea); biochemical tests are usually reserved for premature ovarian insufficiency or post-hysterectomy cases.

Q: Which of the following is NOT a long-term benefit of hormone replacement therapy?

Increased duration of menstrual cycles. **Explanation:** The correct answer is **C. Increased duration of menstrual cycles.** **1. Why Option C is correct:** Menopause is physiologically defined by the permanent cessation of menstruation due to the loss of ovarian follicular activity. Hormone Replacement Therapy (HRT) is administered to alleviate vasomotor symptoms and prevent long-term complications of estrogen deficiency. While HRT (specifically cyclical progesterone) may cause "withdrawal bleeding," it does not restore or increase the duration of the natural menstrual cycle. Furthermore, the goal of HRT in postmenopausal women is symptom management, not the restoration of fertility or the menstrual cycle. **2. Why the other options are incorrect:** * **Option A (Colorectal Cancer):** Large-scale studies, including the Women’s Health Initiative (WHI), demonstrated that combined HRT (Estrogen + Progesterone) is associated with a **reduced risk** of colorectal cancer. * **Option B & D (Fractures and BMD):** Estrogen inhibits osteoclast activity. HRT is highly effective in **increasing Bone Mineral Density (BMD)** and significantly **reducing the risk of osteoporotic fractures** (hip and vertebral). This is considered one of its primary long-term benefits. **3. NEET-PG High-Yield Pearls:** * **Indications:** The primary indication for HRT is moderate-to-severe vasomotor symptoms (hot flashes). * **Window of Opportunity:** HRT is safest when started within 10 years of menopause or before age 60. * **Risks:** Combined HRT increases the risk of breast cancer (after 3-5 years of use), stroke, and Venous Thromboembolism (VTE). * **Uterus Rule:** If the uterus is intact, **never** give estrogen alone (unopposed estrogen) due to the high risk of endometrial hyperplasia and carcinoma; always add progesterone.

Q: A 36-year-old woman has absence of menses for the last 4 months. Pregnancy test is negative. Serum levels of LH and FSH are raised. Serum estradiol level is low. What do these findings suggest?

Premature menopause. ### Explanation **1. Why Premature Menopause is Correct:** The patient presents with secondary amenorrhea (absence of menses for >3 months) and a hormonal profile indicating **Hypergonadotropic Hypogonadism**. * **Low Estradiol:** Indicates ovarian failure; the ovaries are no longer producing estrogen. * **Raised LH and FSH:** Due to the lack of negative feedback from estrogen and inhibin, the anterior pituitary secretes high levels of gonadotropins (FSH >40 IU/L is typically diagnostic). When this occurs before the age of 40, it is termed **Premature Ovarian Insufficiency (POI)** or Premature Menopause. **2. Why Other Options are Incorrect:** * **Bilateral Tubal Obstruction:** This causes infertility but does not affect the hormonal axis or the menstrual cycle, as the ovaries and uterus remain functional. * **PCOD:** Characterized by hyperandrogenism and chronic anovulation. Hormonally, there is typically an **increased LH:FSH ratio (2:1 or 3:1)**, but FSH is usually normal or low, and estrogen is not deficient (often elevated due to peripheral conversion). * **Exogenous Estrogen Administration:** This would lead to **low LH and FSH** levels due to artificial negative feedback on the hypothalamus and pituitary. **3. High-Yield Clinical Pearls for NEET-PG:** * **Definition:** Menopause occurring before age 40. * **Most Common Karyotype Abnormality:** Turner Syndrome (45,XO) or Mosaicism (45,X/46,XX). * **Fragile X Premutation:** The most common genetic cause of "sporadic" POI. * **Diagnostic Criteria:** Amenorrhea for $\geq$ 4 months with FSH levels in the menopausal range (usually $>25-40$ IU/L) on two occasions at least 4 weeks apart. * **Management:** Hormone Replacement Therapy (HRT) is mandatory until the age of natural menopause (approx. 50 years) to prevent osteoporosis and cardiovascular disease.

Q: A 49-year-old female was prescribed hormone replacement therapy. Hormone replacement therapy is useful in all of the following conditions, EXCEPT:

Coronary heart disease. **Explanation:** The correct answer is **Coronary heart disease (D)**. While estrogen was historically thought to be cardioprotective, major clinical trials like the **Women’s Health Initiative (WHI)** and HERS study demonstrated that Hormone Replacement Therapy (HRT) does not provide primary or secondary prevention against coronary heart disease (CHD). In fact, initiating HRT in older postmenopausal women (especially those >10 years post-menopause) may actually **increase the risk** of thromboembolic events and cardiovascular complications. **Analysis of Options:** * **A. Flushing:** Vasomotor symptoms (hot flashes/flushing) are the most common indication for HRT. Estrogen stabilizes the thermoregulatory center in the hypothalamus, providing rapid relief. * **B. Osteoporosis:** Estrogen inhibits osteoclast activity. HRT is highly effective in preventing postmenopausal bone loss and reducing the risk of vertebral and hip fractures. * **C. Vaginal Atrophy:** Estrogen maintains the thickness and vascularity of the vaginal epithelium. Local or systemic HRT is the gold standard treatment for urogenital atrophy (dryness, dyspareunia). **High-Yield Clinical Pearls for NEET-PG:** * **The "Window of Opportunity" Hypothesis:** HRT is safest and most beneficial when started within 10 years of menopause or before age 60. * **Contraindications to HRT:** Undiagnosed vaginal bleeding, estrogen-dependent tumors (Breast/Endometrial CA), active thromboembolism (DVT/PE), and active liver disease. * **Progesterone Addition:** In women with an intact uterus, progesterone must always be added to estrogen to prevent **endometrial hyperplasia/carcinoma**. * **Lipid Profile:** Oral estrogen increases HDL and decreases LDL, but it also increases **Triglycerides**.

Q: Postmenopausal hormone replacement therapy decreases the incidence of which malignancy?

Colorectal. **Explanation:** The correct answer is **Colorectal cancer**. Large-scale clinical trials, most notably the **Women’s Health Initiative (WHI)**, have demonstrated that combined Hormone Replacement Therapy (HRT) with estrogen and progestin is associated with a **significant reduction (approximately 30-40%)** in the risk of colorectal cancer. The underlying mechanism is believed to involve estrogen’s ability to decrease the production of secondary bile acids (which are carcinogenic to the colonic mucosa) and its direct inhibitory effect on the growth of colonic epithelial cells via estrogen receptors (ER-β) in the gut. **Analysis of Incorrect Options:** * **A. Breast Cancer:** Long-term use of combined HRT (Estrogen + Progestin) is a well-known risk factor for breast cancer. Estrogen-only therapy has a lower risk but is not protective. * **C. Ovarian Cancer:** Most epidemiological studies suggest that long-term HRT use slightly **increases** the risk of ovarian cancer (particularly serous and endometrioid types). * **D. Endometrial Cancer:** Unopposed estrogen therapy in women with an intact uterus significantly increases the risk of endometrial hyperplasia and carcinoma. While adding progestin mitigates this risk, HRT does not decrease the baseline incidence. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Indication for HRT:** Moderate to severe vasomotor symptoms (hot flashes, night sweats). * **Bone Health:** HRT is highly effective in preventing **osteoporotic fractures**, but it is generally not the first-line treatment for osteoporosis alone due to other risks. * **Cardiovascular Risk:** HRT increases the risk of **Venous Thromboembolism (VTE)**, stroke, and coronary heart disease (if started late in menopause). * **The "Window of Opportunity" Hypothesis:** HRT is safest and most beneficial when started in women under 60 years of age or within 10 years of menopause onset.

Q: Hormone therapy in postmenopausal women is indicated for treatment of all the following conditions EXCEPT:

Cardiovascular disease. **Explanation:** The correct answer is **Cardiovascular disease (D)**. While estrogen was historically thought to be cardioprotective, major clinical trials like the **Women’s Health Initiative (WHI)** demonstrated that Hormone Replacement Therapy (HRT) does not prevent primary or secondary cardiovascular events. In fact, initiating HRT in older postmenopausal women may increase the risk of stroke and thromboembolism. Therefore, HRT is strictly **contraindicated** for the sole purpose of cardiovascular protection. **Analysis of other options:** * **Vasomotor symptoms (A):** This is the **most common indication** for HRT. Estrogen effectively treats "hot flashes" and night sweats by stabilizing the thermoregulatory center in the hypothalamus. * **Osteoporosis (B):** Estrogen inhibits osteoclast activity. HRT is FDA-approved for the prevention of postmenopausal osteoporosis, particularly in women at high risk of fractures who cannot tolerate other therapies. * **Vaginal atrophy (C):** Also known as Genitourinary Syndrome of Menopause (GSM), estrogen restores vaginal pH and moisture. For isolated vaginal symptoms, local (topical) estrogen is preferred over systemic therapy. **High-Yield NEET-PG Pearls:** 1. **The "Window of Opportunity" Hypothesis:** HRT is safest and most effective when started within 10 years of menopause or before age 60. 2. **Progesterone Addition:** In women with an **intact uterus**, progesterone must be added to estrogen to prevent endometrial hyperplasia and carcinoma. 3. **Contraindications:** Undiagnosed abnormal uterine bleeding, active liver disease, history of breast cancer, and active thromboembolism (DVT/PE). 4. **Drug of choice for premature ovarian insufficiency:** HRT is mandatory until the natural age of menopause (approx. 50 years) to protect bone and heart health.

Q: The rise in FSH during menopause is primarily attributed to which of the following physiological changes?

Decreased ovarian inhibin secretion. **Explanation:** The hallmark of the menopausal transition is a significant rise in **Follicle Stimulating Hormone (FSH)**. This occurs primarily due to the depletion of the ovarian follicle pool. **Why Option B is Correct:** In a functioning ovary, **Inhibin B** (secreted by granulosa cells of antral follicles) provides a potent negative feedback signal specifically to the anterior pituitary to suppress FSH secretion. As the number of follicles declines during perimenopause and menopause, **Inhibin B levels drop first**, even before estradiol levels significantly fall. This loss of negative feedback is the earliest and most significant trigger for the rise in FSH. **Analysis of Incorrect Options:** * **Option A:** While estradiol levels eventually fall, **Inhibin B is the primary regulator of FSH**. Estradiol provides feedback to both the hypothalamus and pituitary, but its decline usually occurs later in the transition compared to the drop in Inhibin. * **Option B:** In menopause, GnRH frequency and amplitude actually **increase** (not decrease) due to the lack of negative feedback from ovarian steroids. * **Option D:** **Anti-Müllerian Hormone (AMH)** levels **decrease** (not increase) as the primordial follicle pool is exhausted. AMH is currently considered the most sensitive marker for ovarian reserve. **High-Yield Clinical Pearls for NEET-PG:** * **Earliest biochemical marker** of ovarian aging: Decreased **Inhibin B**. * **Best marker for ovarian reserve**: **AMH** (levels are cycle-independent). * **Diagnostic FSH level for menopause**: **>40 IU/L** (though >25-30 IU/L is often seen in the transition). * The **LH/FSH ratio** reverses in menopause (FSH > LH) because FSH has a slower clearance rate from the circulation.

Question 1

Hormone replacement therapy is not indicated for which of the following conditions?

Accepted Answer

Prevention of coronary artery disease

Answer

Urogenital atrophy

Answer

Vasomotor symptoms

Answer

Prevention of osteoporosis

Question 2

Menopause is diagnosed by which of the following biochemical parameters?

Accepted Answer

FSH>40 IU/L

Answer

Estradiol >20 pg/ml

Answer

Progesterone <40 ng/dl

Answer

LH<20 IU/L

Question 3

Which of the following cells predominate on vaginal cytology in menopausal women?

Accepted Answer

Parabasal cells

Answer

Intermediate cells

Answer

Superficial cells

Answer

Superficial cells and intermediate cells

Question 4

Which of the following is NOT a long-term benefit of hormone replacement therapy?

Accepted Answer

Increased duration of menstrual cycles

Answer

Decreased rate of colorectal cancer

Answer

Decreased rate of fracture

Answer

Increased bone mineral density

Question 5

A 58-year-old postmenopausal woman on estrogen replacement therapy complains of recent onset of spotting. A bimanual pelvic examination is unremarkable. What is the most likely diagnosis?

Accepted Answer

Endometrial hyperplasia

Answer

Cervical carcinoma

Answer

Cervical polyp

Answer

Dysfunctional uterine bleeding

Question 6

A 36-year-old woman has absence of menses for the last 4 months. Pregnancy test is negative. Serum levels of LH and FSH are raised. Serum estradiol level is low. What do these findings suggest?

Accepted Answer

Premature menopause

Answer

Bilateral tubal obstruction

Answer

Polycystic ovarian disease (PCOD)

Answer

Exogenous estrogen administration

Question 7

A 49-year-old female was prescribed hormone replacement therapy. Hormone replacement therapy is useful in all of the following conditions, EXCEPT:

Accepted Answer

Coronary heart disease

Answer

Flushing

Answer

Osteoporosis

Answer

Vaginal atrophy

Question 8

Postmenopausal hormone replacement therapy decreases the incidence of which malignancy?

Accepted Answer

Colorectal

Answer

Breast

Answer

Ovarian

Answer

Endometrial

Question 9

Hormone therapy in postmenopausal women is indicated for treatment of all the following conditions EXCEPT:

Accepted Answer

Cardiovascular disease

Answer

Vasomotor symptoms

Answer

Osteoporosis

Answer

Vaginal atrophy

Question 10

The rise in FSH during menopause is primarily attributed to which of the following physiological changes?

Accepted Answer

Decreased ovarian inhibin secretion

Answer

Diminished estradiol feedback

Answer

Decreased GnRH frequency

Answer

Increased AMH concentration

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?